TRPC6 and early-onset autosomal dominant Alzheimer disease: Since it has been reported that transcranial ultrasound neuromodulation ameliorates brain pathologies and behavior abnormalities of animal models for neurodegenerative disorders, such as Parkinson’s Disease and Alzheimer’s Disease (51, 52), TRPC6 may contribute to the beneficial mechanism in ultrasound neuromodulation and can also be an attractive pharmacological target for disease-modifying therapies.